Partner Opportunities
Angelica is committed to advancing its own portfolio of fusion toxin drugs based on the DIDT platform. However, we invite proposals for strategic partnerships, including codevelopment arrangements.

A party interested in accessing Angelica's proprietary DIDT technology for developing its own fusion toxin drug should inquire as to the availability for its particular target. Our licensing strategy is target exclusive. A standard term sheet can be provided upon request.